BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares.

Tom Cruise may be Hollywood’s king of death-defying stunts, but he’s got nothing on Nathan Fielder, who concludes Season 2 of The Rehearsal with a feat of mad, mind-boggling genius guaranteed to leave ...

As per Vantage Market Research, the Global Genomic Biomarkers Market has steadily grown due to the increasing demand for ...

Investment management company Vulcan Value Partners recently released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The first quarter experienced the return of ...